Cargando…
Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor as a third-line and subsequent treatment for patients with small cell lung cancer (SCLC) in China. The neurotoxicity is less reported. Posterior reversible encephalopathy syndrome (PRES) is characterized by headaches, seizures, encephalop...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939648/ https://www.ncbi.nlm.nih.gov/pubmed/36814495 http://dx.doi.org/10.3389/fphar.2023.1126235 |